Beyond tissue-factor targeting, HER2-directed ADCs such as trastuzumab deruxtecan (T-DXd) have shown clinically meaningful activity across gynecologic cancer, with real-world and pan-tumor data supporting benefit in HER2-expressing disease and case evidence emerging in 2025 for cervical primaries [135,136,137]. Here, ERBB2 is linked to neoplasm.